BDIC 2025 Shanghai Summit: Bio International Platform for Biopharm Innovation & Collaboration

1. Conference Background and Significance: A Focus on Bio International Collaboration

Against the backdrop of the sustained rapid development of the global biopharmaceutical and Bio International progress, biopharmaceuticals have emerged as a core driving force for medical progress due to their unique therapeutic advantages and vast growth potential
industry, biopharmaceuticals have emerged as a core driving force for medical progress due to their unique therapeutic advantages and vast growth potential.
From addressing intractable diseases to enhancing treatment efficacy and safety, biopharmaceuticals demonstrate potential that traditional drugs cannot match.
Traditional biopharmaceuticals such as monoclonal antibodies, vaccines, and recombinant proteins maintained steady growth of 8% to 16% between 2020 and 2025, while emerging biopharmaceuticals like cell and gene therapy, bispecific antibodies, and antibody-drug conjugates grew at an astonishing rate of 30% to 71%.
According to Frost & Sullivan’s forecast data, the global cell and gene therapy market is projected to surge from USD 2.08 billion in 2020 to USD 30.54 billion by 2025, reflecting a compound annual growth rate (CAGR) of 71%.
China’s market performance is even more impressive, surging from RMB 23.8 million in 2020 to a peak of RMB 17.885 billion in 2025, representing a vertical climb of 276%.

Asia’s role in the global biopharmaceutical landscape is increasingly prominent, driven by enhanced research capabilities, a large and diverse patient population, improving policy support, and ample funding, positioning it as a rapidly emerging hub for biopharmaceutical research and innovation. China’s biopharmaceutical market size grew from 257.65 billion yuan in 2018 to 454.17 billion yuan in 2024, and is expected to reach 460 billion yuan by 2025. Chinese pharmaceutical companies are making continuous breakthroughs in innovative drug R&D. For example, BeiGene’s independently developed BTK inhibitor Zebrutinib achieved sales of 1.742 billion US dollars in the first half of 2025, ranking 46th on the global pharmaceutical sales TOP50 list, becoming the first domestically developed innovative drug to enter the list. Numerous innovative achievements are continuously emerging, not only bringing tangible improvements to the health and well-being of people in the Asian region but also exerting a profound influence on the global biopharmaceutical industry landscape.

Against this macro backdrop, the 7th BioPharmaceutical Developers Innovation Conference (2025 BDIC) was launched with a special mission: to gather global wisdom and resources in the biopharmaceutical field, build a high-end platform for in-depth exchange and cooperation, drive biopharmaceutical R&D innovation to new heights, and further consolidate and enhance Asia’s position and influence in the global biopharmaceutical industry.

1.1 Why should international participants not miss this event?

1.1.1 Cutting-edge technology coverage:

Deep focus on breakthrough areas such as ADCs (antibody-drug conjugates), CGT (cell and gene therapy), bispecific/multispecific antibodies, nanobodies, TCR-T, NK cell therapy, and more.

1.1.2. Comprehensive Industry Chain Analysis:

Covering the entire drug lifecycle from target discovery, CMC processes (Chemistry, Manufacturing, and Control) to clinical development and commercialization.

1.1.3. Asian Market Hub:

China’s biopharmaceutical market is growing at an annual rate exceeding 20%. This summit serves as a strategic foothold for entering the Asia-Pacific market.

2. Conference Basic Information

• Conference Name: 
  • 7th BioPharma Developer Innovation Conference (2025 BDIC)
• Conference Date: 
  • August 21–22, 2025
• Conference Location: 
  • Shanghai, China

2.1. Organizer:

This conference is organized by Informa Exhibitions, a renowned and experienced group in the biopharmaceutical industry. The organizer has long been dedicated to promoting communication and development within the biopharmaceutical sector, having successfully hosted numerous influential industry events such as the BioPharma Asia Convention. It has achieved remarkable results in integrating global resources, leading industry trends, and fostering collaboration between academia, research, and industry, with a strong industry presence and significant influence.

2.2. Supporting Organizations:

Numerous authoritative institutions, industry associations, and well-known enterprises from both domestic and international sectors have joined as supporting organizations. These include the China Pharmaceutical Biotechnology Association, the Pharmaceutical Research and Manufacturers of America (PhRMA), Johnson & Johnson, and Roche. These supporting organizations leverage their resource advantages, professional capabilities, and industry influence to provide comprehensive support for the conference, from professional guidance and resource matching to promotion and logistical support, ensuring the conference operates at a high standard and quality.

3. Conference Objectives and Expected Outcomes: Fostering Bio International Collaboration

3.1. Promoting Knowledge Exchange and Sharing:

The conference aims to bring together leading global experts, scholars, corporate executives, and regulatory representatives in biopharmaceutical research and development. Through diverse formats such as keynote speeches, specialized reports, and panel discussions, participants will comprehensively and deeply share and exchange the latest research findings, cutting-edge technological advancements, innovative R&D concepts, and successful practical experiences in the biopharmaceutical field. Whether it is breakthroughs in the development of new antibody drugs or clinical application progress in cell and gene therapy technologies, participants can obtain first-hand information, broaden their knowledge horizons, and grasp the pulse of industry development.

3.2. Promoting Collaboration and Innovation:

The conference will establish an efficient collaboration platform for all participants, facilitating precise matching between biopharmaceutical companies and research institutions to promote deep integration between industry, academia, and research. On one hand, companies can use this platform to identify promising research projects and innovative technologies, accelerate R&D processes, and enhance their core competitiveness. On the other hand, research institutions can more smoothly achieve industrialization of their innovative achievements, creating value for society. Additionally, by promoting collaboration and exchange among companies, the conference drives coordinated development across the entire industry chain, fostering new innovative cooperation models and solutions, and injecting continuous innovative vitality into the biopharmaceutical industry.

3.3. Addressing Industry Challenges and Formulating Strategies:

Addressing the common challenges faced in biopharmaceutical R&D, such as high R&D costs, lengthy R&D cycles, complex clinical trial designs, stringent regulatory requirements, and intense market competition, the conference will bring together industry experts for in-depth discussions. Participants will analyze the root causes of these issues, explore feasible strategies and solutions, and assist companies and R&D teams in optimizing R&D pathways, reducing risks, improving R&D efficiency and success rates, and promoting the healthy and sustainable development of the entire biopharmaceutical industry.

3.4. Shaping Industry Development Trends:

Leveraging the cutting-edge insights and abundant resources gathered at the conference, conduct forward-looking analyses and forecasts of future trends in the global biopharmaceutical industry. By discussing the application prospects of emerging technologies, shifts in market demand trends, and adjustments in policy and regulatory directions, provides strategic decision-making references for attendees, guides enterprises to proactively position themselves, seize market opportunities, and gain a competitive edge in the intense global landscape, collectively shaping the future development trajectory of the biopharmaceutical industry.

4. Highlights of the Conference Agenda

Must-see key technologies and case studies

4.1. Breakthroughs in ADC Technology

• Fudan Zhangjiang ADC Patent:
  • A novel linker design (structural formula Ab-(L3-L2-L1-D)m) significantly reduces toxicity and side effects while enhancing the rate of enzymatic cleavage within tumor cells, opening a new pathway for camptothecin-based ADCs.

• Case Study:
  • Lingke Pharmaceuticals (Hangzhou)‘s Series B financing project (led by Lilly Asia Ventures) focuses on the development of ADCs for drug-resistant tumors.

4.2. Cell Therapy Process Upgrades

• Closed Production Systems:
  • Li Song, Vice President of R&D at Yimingangke, will share strategies for automation and cost control in CAR-T production.

• Allogeneic Therapy Quality Control:
  • Lv Fenghua, Senior Director of CMC at Best Bio, will explain residual protein detection technology for host cells in universal CAR-NK therapies.

4.3. Clinical Translation of Multi-Antibody Drugs

• Fang Yongliang, COO of Dao Bio:
  • Applications of multi-specific antibodies (triple/quadruple antibodies) in metabolic diseases.

• Wang Anxin, R&D Director of Hode Bio:
  • Blood-brain barrier penetration strategies for multi-antibodies in the treatment of CNS diseases.

5. Opening Ceremony and Keynote Speeches

During the opening ceremony, executives from internationally renowned biopharmaceutical companies, academic leaders from top research institutions, and officials from authoritative regulatory agencies will be invited to deliver speeches. They will provide a macro-level interpretation of the current state of the global biopharmaceutical industry, as well as the opportunities and challenges it faces, from diverse perspectives, setting the tone for the entire conference.

The keynote speech session will feature several experts and scholars who have made outstanding contributions and exerted significant influence in the field of biopharmaceuticals. For example, Professor George Church from Harvard Medical School will deliver a speech titled “Frontier Trends and Breakthrough Technologies in Global Biopharmaceutical R&D,” delving into the hottest research directions, such as AI-driven drug design and the expanded application of mRNA technology in novel vaccines and therapeutic drugs; Peter Marks, Director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration (FDA), will focus on “Innovative Design and Efficient Implementation Strategies for Biopharmaceutical Clinical Trials,” sharing practical case studies on how to optimize clinical trial processes, enhance trial success rates and data quality, shorten R&D timelines, and reduce R&D costs.

5.1. Specialized Forums

5.1.1 Antibody Drug Development Forum:

As the mainstay of the biopharmaceutical field, antibody drugs have always been a key focus and hot topic in research and development. This forum will delve into core issues such as the design and development of novel antibody structures, the optimization and clinical application of antibody-drug conjugates (ADCs), and the latest advancements in the development of bispecific and multispecific antibodies. Research and development leaders from global pharmaceutical companies such as Roche and Innovent Biologics will share their successful experiences and key technological breakthroughs in antibody drug development. Additionally, experts from research institutions such as the Antibody Drug Development Center at Tsinghua University will present the latest research findings and cutting-edge technologies, providing attendees with comprehensive and in-depth industry insights.

5.1.2 Cell and Gene Therapy Forum:

Cell and gene therapy, as a highly promising emerging therapeutic modality, has made remarkable progress in recent years. This forum will cover topics such as the optimization and clinical application of immune cell therapy technologies like CAR-T and CAR-NK, the exploration of gene editing technologies like the CRISPR/Cas system in disease treatment, and research findings and clinical translation of stem cell therapy across various disease areas. Experts will collectively discuss how to address challenges in large-scale production, safety assessment, and improving clinical efficacy in cell and gene therapy, driving the rapid development of this cutting-edge field. For example, Professor Carl June from the University of Pennsylvania will share the latest breakthroughs in CAR-T cell therapy for solid tumors.

5.1.3 Biopharmaceutical Production Processes and Quality Control Forum:

Efficient, stable production processes and strict quality control are critical to ensuring biopharmaceuticals transition from the laboratory to the market. This forum will focus on upstream cell culture technologies, optimization and innovation of downstream purification processes, the application of single-use technologies in biopharmaceuticals, and the application of process analytical technology (PAT) for real-time monitoring and control of production processes. It will also delve into the latest standards and regulatory requirements for biopharmaceutical quality control, as well as how to establish a comprehensive quality management system to ensure the quality and safety of biopharmaceutical products. Companies such as WuXi Biologics will share their advanced production process experiences.

5.1.4 Biopharmaceutical Clinical Research and Regulatory Affairs Forum:

Clinical research is a critical step in verifying the efficacy and safety of biopharmaceuticals, while regulatory affairs span the entire process of biopharmaceutical R&D, production, and sales. This forum will invite senior clinical research experts to share their practical experience in areas such as biopharmaceutical clinical trial protocol design, subject recruitment and management, and clinical data monitoring and analysis, as well as how to address various issues and challenges that arise during clinical trials. Additionally, regulatory affairs experts will provide detailed interpretations of the latest changes in domestic and international regulations and policies related to biopharmaceuticals, as well as strategies and methods for companies to comply with regulatory requirements, helping participating companies ensure the compliance of their R&D and production activities. For example, experts from the Drug Evaluation Center of the China National Medical Products Administration will interpret the latest domestic regulations and policies.

6. Industry Matchmaking and Cooperation Negotiation Session: Catalyzing Bio International Partnerships

To promote cooperation and exchange among participants, the conference has specially organized an industry matchmaking and cooperation negotiation session. During this session, biopharmaceutical companies, research institutions, CRO/CDMO companies, investment institutions, and other entities will have the opportunity to engage in one-on-one in-depth discussions to explore potential cooperation opportunities. Companies can showcase their R&D achievements, technological advantages, and cooperation needs; research institutions can promote research projects with industrialization potential; CRO/CDMO companies can introduce their professional service capabilities; and investment institutions can identify high-quality projects with investment value. Through precise matching, the event aims to achieve resource sharing, complementary advantages, and promote the coordinated development of the biopharmaceutical industry chain.

7. Closing Ceremony and Future Outlook

At the closing ceremony, the discussion outcomes and cooperation intentions reached during the conference will be summarized and reviewed, and individuals and teams who have made outstanding contributions to biopharmaceutical R&D innovation will be honored. Additionally, industry leaders will be invited to provide insights and suggestions on the future development of the biopharmaceutical industry, including research directions, cooperation models, and industry trends, to guide participants toward future efforts and inspire continued innovation in the biopharmaceutical field.

8. Participating Institutions and Expert Lineup

8.1. Participating Institutions

8.1.1. Biopharmaceutical Companies:

The event has attracted numerous renowned biopharmaceutical companies from around the world, including international pharmaceutical giants such as Johnson & Johnson, Roche, Novartis, and Pfizer, as well as emerging biotechnology companies making waves in the biopharmaceutical field, such as Innovent Biologics, Junshi Biosciences, and Rongchang Biopharmaceuticals. These companies possess extensive experience and strong capabilities across all stages of biopharmaceutical research, development, production, and sales. They will showcase their latest research achievements and product pipelines at the conference, as well as share successful business models and market expansion strategies.

8.1.2. Research Institutions:

The participation of numerous top-tier research institutions has infused the conference with strong academic strength. Research teams from renowned domestic and international research institutions and universities, including the National Institutes of Health (NIH) in the United States, the Chinese Academy of Sciences, the University of Cambridge in the United Kingdom, and Stanford University in the United States, will attend the conference. They will present cutting-edge research findings and innovative research concepts, providing new inspiration and direction for basic and applied research in the biopharmaceutical field, and promoting deep integration and collaboration between industry, academia, and research.

8.1.3. CRO/CDMO Companies:

CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) companies play a crucial supporting role in the research, development, and production of biopharmaceuticals. The conference will bring together a group of leading global CRO/CDMO companies, such as WuXi AppTec, Kanglong Chemical, and Boteng Co., Ltd. These companies will showcase their professional service capabilities and advanced technological platforms, offering one-stop solutions for biopharmaceutical companies from preclinical research to clinical trials, and from process development to large-scale production. This will help companies improve R&D efficiency, reduce costs, and accelerate the market launch of biopharmaceuticals.

8.1.4. Investment Institutions:

The high investment, high risk, and high return characteristics of the biopharmaceutical field have attracted significant attention from investment institutions. This conference will invite renowned domestic and international investment institutions to participate, such as Sequoia Capital, Hillhouse Capital, and Temasek. They will engage in in-depth discussions with biopharmaceutical companies and research institutions during the conference to identify projects with investment potential, provide financial support for biopharmaceutical R&D innovation, and share their analyses and insights into investment trends and market prospects in the biopharmaceutical sector, offering financial perspectives and recommendations for industry development.

8.2. Expert Lineup

Special Guests: 60+ Leaders (partial list)

Name	Organization	Position	Presentation Topic
Yue Liu	Ab Studio	CEO	ADC’s AI-driven development
Tan Binghe	Jihui Bio	Vice President of Manufacturing and CMC	Continuous production process optimization
Tu Chao	Boao Mingcai	Founder & CEO	Dual antibody target combination strategy
Hou Bing	Deqi Medicine	Vice President	Clinical development of ADCs for solid tumors
Wang Wenshi	Fosun Kairui	Senior Vice President of Technical Operations	Cell therapy quality control system
Hu Liaoyuan	Youzhiyou Bio	Chief Scientific Officer	Nanoantibody blood-brain barrier penetration technology

8.3. Distribution of participants

• Biotech/Biopharma companies: 60%
• Biopharmaceutical CDMOs: 9%
• Bioprocessing solution providers: 8%
• CRO institutions: 7%
• Investment and consulting institutions: 5%
• Hospitals and research institutions: 2%

8.4. Job distribution:

• General Manager/President: 57%
• Director: 23%
• Manager/Engineer: 16%

8.5. Internationally Renowned Experts:

The conference has invited several renowned experts and scholars in the field of international biopharmaceuticals to serve as speakers and panelists. For example, Professor Carl June is a leading figure in the global field of cell therapy and has achieved groundbreaking results in the research and development, and clinical application of CAR-T cell therapy technology. He will share the latest research progress and clinical practice experience in cell therapy technology on a global scale at the conference. Professor Drew Weissman is a pioneer in mRNA technology and has made outstanding contributions to the research and development of mRNA vaccines and therapeutic drugs. He will deliver an insightful presentation on the cutting-edge applications of mRNA technology for conference participants.

8.6. Domestic Authority Experts:

Authority experts in the field of biopharmaceuticals in China will also gather at this conference. Academician Chen Sajuian is the chief scientist of the Chinese Academy of Sciences and has conducted in-depth research in the field of gene therapy for many years, achieving a series of scientific research results with independent intellectual property rights. She will share the challenges and solutions faced in the clinical translation of gene therapy technology based on the current development status of the domestic gene therapy industry. Dr. Xu Jianfeng is the R&D director at Innovent Biologics, with extensive practical experience in optimizing biopharmaceutical production processes and quality control. He will introduce the company’s successful experiences and innovative practices in the industrial-scale production of biopharmaceuticals at the conference.

9. Conference-related activities: Showcasing Bio International Innovation and Exchange

9.1 Exhibition of innovative achievements in biopharmaceutical research and development

In order to more intuitively showcase the latest research and development achievements and innovative technologies in the field of biopharmaceuticals, an exhibition of innovative achievements in biopharmaceutical research and development will be held during the conference. The exhibition will feature multiple zones showcasing novel antibody drugs, cell and gene therapy products, biopharmaceutical production equipment and technology, diagnostic reagents and instruments, and more. Participating companies and institutions will present their research achievements and technological advantages through physical displays, model demonstrations, multimedia presentations, and other methods. Attendees can engage in face-to-face discussions with exhibitors at the exhibition site to gain deeper insights into innovation trends in the biopharmaceutical field and explore potential collaboration opportunities.

9.2 On-site visits

To provide attendees with a deeper understanding of the actual R&D and production operations of biopharmaceutical companies, the conference will organize on-site visits to representative biopharmaceutical companies and R&D institutions in Shanghai. The visits will include biopharmaceutical R&D centers with advanced R&D facilities and innovative technology platforms, as well as biopharmaceutical production bases with large-scale, high-quality production capabilities, such as WuXi Biologics’ Shanghai Lingang Base. During the site visits, relevant personnel from the companies and institutions will provide participants with detailed introductions to their R&D processes, production technologies, quality management systems, and other aspects, and arrange on-site interactive exchange sessions to address participants’ questions. Through these site visits, participants will be able to integrate theoretical knowledge with practical applications, gaining a more intuitive and in-depth understanding of the biopharmaceutical industry.

9.3 Social Activities

In addition to professional academic exchanges and business negotiations, the conference has also carefully arranged a series of social activities aimed at providing participants with a relaxed and pleasant atmosphere for communication and promoting mutual understanding and cooperation. Social activities include a welcome banquet, cocktail reception, and tea break networking sessions. During these events, participants can relax from work pressures, connect with peers from around the world in a casual setting, expand their professional networks, and establish long-term cooperative relationships. Additionally, social activities serve as an excellent platform for sharing industry insights, exchanging personal experiences, and fostering mutual understanding and trust among participants, laying a solid foundation for future collaborations.

10. Conference Guidelines

10.1 Registration Information

10.1.1 Registration Period:

The registration portal will officially open on June 1, 2025. We recommend that participants register early to take advantage of the early bird discount. The early bird registration deadline is July 1, 2025, and the regular registration period runs from July 2, 2025, until the day before the conference begins.

10.1.2 Registration Methods:

Participants may register online via the conference’s official website (https://www.2025bdic.com). During the registration process, participants must complete personal basic information, organizational information, conference attendance requirements, and select the appropriate registration type (e.g., general attendee, student attendee, corporate group attendee, etc.). Upon successful registration, the system will automatically send a confirmation email to the registered email address. Participants must keep the confirmation email as proof of registration.

10.1.3 Registration Fees:

Registration fees vary by registration type. During the early bird registration period, the registration fee for general attendees is USD 800. Student attendees with valid student IDs may enjoy a discounted rate of USD 400; Corporate group participants (three or more people) are eligible for a group discount, with each person’s registration fee being USD 700. During the regular registration period, all registration fees will be increased by USD 100. Registration fees include conference materials, lunch and refreshments during the conference, and the welcome dinner, but do not include transportation and accommodation costs.

10.2 Transportation Guide

10.2.1 Airport Transportation:

Shanghai has two international airports: Shanghai Pudong International Airport and Shanghai Hongqiao International Airport. To travel from Pudong International Airport to the conference venue, you can take Metro Line 2 and get off at Longyang Road Station, then transfer to other transportation options to reach the conference hotel. Alternatively, you can take the airport shuttle bus, with multiple routes available. Specific route and stop information can be found on the airport shuttle bus official website. Additionally, you can take a taxi or ride-hailing service, which takes approximately 40 minutes and costs around 150 yuan. From Hongqiao International Airport to the conference venue, transportation is more convenient. You can take Metro Line 2 or Line 10 directly, get off at Nanjing East Road Station, and walk to the conference hotel; taking a taxi or ride-hailing service takes approximately 30 minutes and costs around 100 yuan.

10.2.2 City Transportation:

Shanghai’s city transportation is very convenient, with an extensive subway network that can reach almost every corner of the city. Participants can download the “Metro Metropolis” app and scan the QR code on their phones to ride the subway. Additionally, buses are also a common mode of transportation, and you can check bus routes and stop information at bus stops. If you need to take a taxi, you can hail one on the street or use a ride-hailing app on your phone.

10.3 Accommodation Recommendations

The conference organizers have recommended several nearby hotels to participants, covering different categories and price ranges to meet the diverse needs of participants. Recommended hotels include the Sheraton Shanghai Pudong Riverside Hotel, the Waldorf Astoria Shanghai on the Bund, and the Peace Hotel Shanghai, among others. These hotels are all located near the conference venue, offering convenient transportation, and some hotels also provide free shuttle buses to and from the conference venue. Participants may book accommodations based on their budget and preferences through the official conference website’s booking link or by contacting the hotels directly. When booking, please specify that you are attending the 7th BioPharma Developer Innovation Conference (2025 BDIC) to enjoy the conference’s exclusive discounted rates.

10.4 Visa Application

Participants from abroad need to apply for a Chinese visa. Please prepare the necessary documents in advance based on your nationality and visa type, and visit the Chinese embassy in your country.

11. Why is BIC2025 worth adding to your schedule?

This summit is not only a platform for showcasing technology but also a microcosm of the Asian biopharmaceutical ecosystem:

• Technology Transfer: From Fudan Zhangjiang’s ADC patents to Lingke Pharmaceutical’s industrialization cases, witness the closed-loop process from laboratory to market.
• Global Collaboration: Investment institutions such as Lilly Asia Ventures and Lianxin Capital will attend, revealing trends in the integration of capital and technology.
• Addressing Clinical Challenges: Focusing on unmet needs such as drug-resistant tumors and CNS diseases, providing solutions.

“Ending tuberculosis requires multi-stakeholder collaboration, and BIC2025 is the intersection of technological innovation and industrialization.”
— Zhang Wenhong (Director of the National Center for Infectious Diseases)

12. Past Collaborations and Impact: Building on Bio International Legacy

• Past Partners: 
  • WuXi Biologics, Kanglong Chemical, Boteng Co., Ltd., GenScript Biotech, Roche, Fosun Kite, etc.
• 2024 Data: 
  • TouchBio hosted over 20 summits throughout the year, attracting over 30,000 on-site attendees and covering hot topics such as ADCs, CGT, and nuclear medicine.
• Past Conference Impact:
  • Looking back at the first six editions of the Biopharmaceutical Developers Innovation Conference, each edition has had a significant and far-reaching impact on the global biopharmaceutical industry. The conferences attracted tens of thousands of professionals from around the world, including executives from biopharmaceutical companies, R&D personnel, experts and scholars from research institutions, representatives from CRO/CDMO companies, and practitioners from investment institutions. Through in-depth academic exchanges, efficient business negotiations, and extensive cooperation matching, the conferences facilitated the conversion and application of numerous research achievements, promoted cooperation and innovation among enterprises, and injected strong momentum into the development of the biopharmaceutical industry. Many innovative technologies and R&D achievements first unveiled at the conference later became important milestones in industry development, guiding technological transformations and future directions in the biopharmaceutical field. Additionally, the conference played a positive role in cultivating and expanding the professional talent pool in the biopharmaceutical sector. By organizing various training courses, workshops, and academic lectures, it provided participants with opportunities for learning and professional development, thereby fostering talent growth within the industry.

13. Shanghai 7th Bio-Pharmaceutical Developers Innovation Conference (2025 BDIC) International Exhibitor Consumer Guide

Combining Shanghai’s international characteristics with the core positioning of the 7th Bio-Pharmaceutical Developers Innovation Conference (2025 BDIC), the following recommendations will be presented from four dimensions: cultural landmarks, culinary experiences, business networking, and specialty markets, providing international exhibitors with professional yet locally-rooted consumption and check-in options:

13.1. Cultural Landmarks: A Dialogue Between History and Modernity

• 13.1.1. The Bund & Lujiazui Skyline
  • As Shanghai’s “city emblem,” the Bund’s international architectural ensemble contrasts sharply with Lujiazui’s skyscraper cluster. We recommend international visitors take an evening stroll along the Bund to enjoy the panoramic transformation from the golden hues of sunset to the dazzling nighttime light show. CASANOVA Italian Restaurant (Bund Branch) offers a high-value option at 300 RMB per person, with an outdoor terrace overlooking the Huangpu River. Signature dishes include black truffle pizza and roasted spring chicken. For an ultimate experience, book a table at the POP Terrace Restaurant · Wangjiang Pavilion on the 7th floor of The Bund 3. Enjoy a 270-degree river view paired with American-style steak and Boston lobster, and witness the Pudong light show as night falls.
• 13.1.2. Yuyuan Garden & City God Temple
  • This Ming Dynasty garden is the heart of Jiangnan culture. We recommend visiting early in the morning to avoid the crowds, strolling across the Nine-Turn Bridge and Lake Heart Pavilion, and savoring the serene beauty of the garden. The crab roe xiaolongbao from Nanxiang Steamed Bun Shop and the gourd pastries from Green Wave Corridor are must-try classics. On weekends, the Yuyuan Garden Square often hosts intangible cultural heritage craft workshops (such as paper cutting and dough figurine making), perfect for international visitors to create their own souvenirs.
• 13.1.3. Wukang Road Historical and Cultural District
  • Centered around the Wukang Building, this area blends Spanish-style architecture with independent cafes and art spaces. We recommend starting at the Da Yin Bookstore on the ground floor of Wukang Building, then walking along Xingguo Road to Luo Mi Ouyang Tai (the filming location for the movie “Love Myth”), where you can stop at % Arabica Coffee or Luneurs Ice Cream for a break. This route was praised by the Xinmin Evening News as a “paragon of Citywalk where frozen time and flowing fireworks intertwine.”

13.2. Culinary Experience: A Fusion of Global Flavors and Shanghai Classics

• 13.2.1. Tracing the Origins of CIIE-Featured Delicacies
  • As the CIIE’s “6 days + 365 days” year-round platform, Hongqiao Food Hub features the Global Food Market on B2, showcasing CIIE star products such as Australian beef and Norwegian salmon, while the Hongqiao International Coffee Port on L2 offers Southeast Asian Coffee Festival specialty drinks (e.g., the 8.8 yuan co-branded coffee). while the Expo Wine Cellar Market on the B1 floor offers free tastings of Brazilian non-alcoholic sparkling wine and other specialty beverages. Exhibitors are encouraged to experience global ingredients in one stop here, with some products available for on-site purchase and direct shipping back to China.

• 13.2.2. Michelin-Starred Chefs’ Cross-Border Experiments
  • DA VITTORIO SHANGHAI (The Bund Financial Center):
    • A two-Michelin-starred Italian restaurant that combines Italian seafood cooking philosophy with Chinese ingredients like ten-year-old yellow croaker fish maw. Signature dishes like “Italian-style fish maw pasta” and “steamed yellow croaker” showcase the pinnacle of East-West fusion aesthetics. The wine list features both niche Italian wineries and renowned Burgundy estates.
  • Mercato by Jean-Georges (The Bund No. 3):
    • A high-end Italian restaurant created by the Jean-Georges team, featuring black truffle pizza and lobster dumplings paired with panoramic views of The Bund through floor-to-ceiling windows. The lunch set menu offers excellent value for money, making it ideal for business negotiations.

• 13.2.3. Modern interpretations of local cuisine
  • Fu 1088 (Zhenning Road Old Mansion):
    • Traditional braised pork belly is slow-cooked for hours, resulting in a rich sauce flavor that is fatty yet not greasy; old-style Shanghai-style smoked fish is crispy on the outside and tender on the inside, paired with a caramel sauce for a perfect balance of sweet and salty flavors. The restaurant retains its red brick walls and vintage chandeliers, creating an intimate mansion-style dining atmosphere.
  • Lan Ting Ji (Wuyi Road):
    • A representative of creative Shanghainese cuisine, the black truffle braised pork incorporates the aroma of mushrooms into the rich sauce, while the crab roe rice is still bubbling when served, making it ideal for international diners seeking innovative flavors.

13.3. Business Networking: High-End Settings and Targeted Connections

• 13.3.1. Nanjing West Road Luxury Culture Tour
  • 13.3.1.1. LV Louis Vuitton Concept Space (Nanjing West Road):
    • This ship-shaped building, designed by OM,A is not only a shopping landmark, but also features the “Extraordinary Journey” exhibition on the ground floor, which comprehensively showcases LV’s 171-year maritime history. The rooftop terrace seats at Le Café Louis Vuitton require a two-week reservation and are ideal for hosting small VIP receptions.
  • 13.3.1.2. Shanghai Hong Kong Plaza:
    • Home to the largest Asian flagship stores of brands like Hermès and Chanel, the 6th-floor The Lounge VIP room offers personal styling guidance and bespoke services, ideal for maintaining high-end client relationships.

• 13.3.2.Cross-industry collaboration in the West Bund art district
  • 13.3.2.1. West Bund Art Museum:
    • The permanent exhibition “The Form of Time,” co-organized with the Pompidou Center, explores concepts of time and space through over 200 contemporary artworks. The museum’s café and riverside promenade form an “art + leisure” loop.
  • 13.3.2.2. BFC Bund Financial Center:
    • The “Bund Maple Path” market on Saturdays gathers independent designer brands and handmade delicacies. At night, the Shikumen architecture contrasts with DJ performances, creating a cyberpunk-style ambiance, ideal for hosting themed cocktail parties.

• 13.3.3.Efficient Industry Matching Scenarios
  • 13.3.3.1. Hongqiao PinHui Industry Matching Zone:
    • As a supporting space for the China International Import Expo, it offers bookable one-on-one meeting rooms for on-site production demand matching with CDMO companies like WuXi AppTec and Kanglong Chemical, with some firms providing rapid quotation services for process development.
  • 13.3.3.2. Shanghai International Medical Park:
    • Located approximately 30 minutes by car from the Pudong venue, the WuXi Biologics Lingang Base within the park offers GMP facility tours, providing an intuitive understanding of the large-scale production process for biopharmaceuticals.

13.4. Specialty Markets: Cultural Experiences and Consumer Upgrades

• 13.4.1. University Road Arts Night Market
  • Yangpu District’s University Road Night Market blends artistic ambiance with a lively, bustling atmosphere. It features creative stalls selling handmade silver jewelry and vintage cameras, as well as craft beer bars and street band performances. We recommend trying Blueglass Yogurt’s limited-edition “Molecular Collagen Yogurt” or enjoying a drink at The Nest rooftop bar while overlooking the vibrant night views of the neighborhood.
• 13.4.2. Wukang Road Weekend Market
  • The weekend market at Wukang Building Square focuses on the concept of “sustainable consumption,” gathering local designer brands, organic food, and second-hand luxury goods. Visitors can purchase souvenirs with Shanghai elements, such as metal bookmarks shaped like the Wukang Building and Shikumen architecture puzzles.
• 13.4.3. Suzhou River Industrial Style Check-in
  • Walk along the Suzhou River promenade from the Waibaidu Bridge to the Sihang Warehouse, where you can visit the former Shanghai Match Factory site in Banma Suzhou River Park, contemporary art exhibitions at the M50 Creative Park, and the century-old postal equipment exhibition at the Shanghai Postal Museum. We recommend taking creative photos at the % Arabica coffee terrace on the ground floor of the Riverside Building, with the Suzhou River and Lujiazui skyline as the backdrop.

13.5. Practical Tips

• 13.5.1 Transportation Recommendations:
  • Use the “Metro Metropolis” app to scan and ride the subway. Line 2 covers key areas such as Hongqiao Pinhui (Xujing East Station), Nanjing West Road, and Lujiazui. For the journey from The Bund to Yuyuan Garden, we recommend cycling on a shared bike, which takes approximately 15 minutes to traverse the old city and modern commercial districts.
• 13.5.2. Cultural Adaptation:
  • Some restaurants offer English menus (e.g., DA VITTORIO, CASANOVA). It is recommended to make reservations in advance via Dianping or OpenTable and note “International Guests.” Night market stalls accept Alipay/WeChat Pay, and some merchants provide English communication services.
• 13.5.3. Unique Souvenirs:
  • Snacks from the China International Import Expo (such as Malaysian Mr. Potato Chips and Indonesian Papapong Shrimp Chips) at Hongqiao Pin Hui, “Moonrise over the Sea” themed cultural and creative products (scarves, incense) at the Yu Garden, and hand-drawn maps of Shanghai from the “Da Yin Bookstore” on Wukang Road are all practical and meaningful choices.

Through the above recommendations, international exhibitors can efficiently complete business negotiations while deeply experiencing Shanghai's diverse charm as a “global city laboratory,” achieving dual value in professional exchange and cultural exploration.